Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma

Nitya Nathwani; Joycelynne Palmer; Timothy W. Synold; Behrouz Salehian; Michael Rosenzweig; James F. Sanchez; Samantha N. Hammond; Kehinde Adekola; Valeria Tomarchio; Arnab Chowdhury; Chatchada Karanes; Myo Htut; Firoozeh Sahebi; Tanya Siddiqi; Amrita Krishnan; Stephen J. Forman; Steven T. Rosen

doi:10.1016/j.clml.2020.05.017

Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma

Nitya Nathwani^*, Joycelynne Palmer, Timothy W. Synold, Behrouz Salehian, Michael Rosenzweig, James F. Sanchez, Samantha N. Hammond, Kehinde Adekola, Valeria Tomarchio, Arnab Chowdhury, Chatchada Karanes, Myo Htut, Firoozeh Sahebi, Tanya Siddiqi, Amrita Krishnan, Stephen J. Forman, Steven T. Rosen

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	e667-e672
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	10
DOIs	https://doi.org/10.1016/j.clml.2020.05.017
State	Published - Oct 2020

Funding

Research reported in this publication included work performed at the Analytical Pharmacology Core Facility and the Biostatistics and Mathematical Modeling Core supported by the National Institutes of Health (award P30CA033572 ). The authors acknowledge the Briskin family for support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords

Adverse events
Glucose transporters
Hematologic malignancies
Nelfinavir
Protease inhibitors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2020.05.017

Cite this

Nathwani, N., Palmer, J., Synold, T. W., Salehian, B., Rosenzweig, M., Sanchez, J. F., Hammond, S. N., Adekola, K., Tomarchio, V., Chowdhury, A., Karanes, C., Htut, M., Sahebi, F., Siddiqi, T., Krishnan, A., Forman, S. J., & Rosen, S. T. (2020). Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 20(10), e667-e672. https://doi.org/10.1016/j.clml.2020.05.017

@article{5f04365a91474eedba42b210915d0656,

title = "Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma",

keywords = "Adverse events, Glucose transporters, Hematologic malignancies, Nelfinavir, Protease inhibitors",

author = "Nitya Nathwani and Joycelynne Palmer and Synold, {Timothy W.} and Behrouz Salehian and Michael Rosenzweig and Sanchez, {James F.} and Hammond, {Samantha N.} and Kehinde Adekola and Valeria Tomarchio and Arnab Chowdhury and Chatchada Karanes and Myo Htut and Firoozeh Sahebi and Tanya Siddiqi and Amrita Krishnan and Forman, {Stephen J.} and Rosen, {Steven T.}",

note = "Funding Information: Research reported in this publication included work performed at the Analytical Pharmacology Core Facility and the Biostatistics and Mathematical Modeling Core supported by the National Institutes of Health (award P30CA033572 ). The authors acknowledge the Briskin family for support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ",

year = "2020",

month = oct,

doi = "10.1016/j.clml.2020.05.017",

language = "English (US)",

volume = "20",

pages = "e667--e672",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "10",

}

Nathwani, N, Palmer, J, Synold, TW, Salehian, B, Rosenzweig, M, Sanchez, JF, Hammond, SN, Adekola, K, Tomarchio, V, Chowdhury, A, Karanes, C, Htut, M, Sahebi, F, Siddiqi, T, Krishnan, A, Forman, SJ & Rosen, ST 2020, 'Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 20, no. 10, pp. e667-e672. https://doi.org/10.1016/j.clml.2020.05.017

TY - JOUR

T1 - Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma

AU - Nathwani, Nitya

AU - Palmer, Joycelynne

AU - Synold, Timothy W.

AU - Salehian, Behrouz

AU - Rosenzweig, Michael

AU - Sanchez, James F.

AU - Hammond, Samantha N.

AU - Adekola, Kehinde

AU - Tomarchio, Valeria

AU - Chowdhury, Arnab

AU - Karanes, Chatchada

AU - Htut, Myo

AU - Sahebi, Firoozeh

AU - Siddiqi, Tanya

AU - Krishnan, Amrita

AU - Forman, Stephen J.

AU - Rosen, Steven T.

N1 - Funding Information: Research reported in this publication included work performed at the Analytical Pharmacology Core Facility and the Biostatistics and Mathematical Modeling Core supported by the National Institutes of Health (award P30CA033572 ). The authors acknowledge the Briskin family for support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2020/10

Y1 - 2020/10

KW - Adverse events

KW - Glucose transporters

KW - Hematologic malignancies

KW - Nelfinavir

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85087411752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087411752&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.05.017

DO - 10.1016/j.clml.2020.05.017

M3 - Article

C2 - 32631779

AN - SCOPUS:85087411752

SN - 2152-2650

VL - 20

SP - e667-e672

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 10

ER -

Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this